Turnstone Biologics Corp.
TSBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -73.7% | -27.6% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 85.5% | 97% | 98% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -291.3% | -38.9% | 35.3% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -285.9% | -42.1% | 32.8% |
| EPS Diluted | -3.07 | -2.73 | -1.39 | 1.5 |
| % Growth | -12.5% | -96.4% | -192.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |